基础与转化医学研究中心
返回科室
蔡佩娥
职称：研究员
科室：基础与转化医学研究中心
概述

中山大学百人计划引进人才，论文润色小组组长及学术规范办公室主任。2014-2015、2015-2017曾作为博士后先后在韩国先进科学技术研究院、美国哈佛大学医学院学习和工作3年。2018年任职于中山大学孙逸仙纪念医院研究员。目前研究利用多种生物响应型纳米给药系统靶向调节肿瘤微环境用于肿瘤免疫治疗。负责广东省自然科学基金-杰出青年项目、国家自然科学基金面上项目、High-level Talent Special Funding Scheme of Sun Yat-Sen Memorial Hospital、The Research Fund for International Young Scientists、国家自然青年科学基金项目等多个课题项目，获批“三个三”工程青年拔尖人才、中山大学优秀青年教师培育等项目。围绕“高分子纳米材料”和“肿瘤靶向治疗”方向在Cancer Cell (IF 48.8), Advanced Materials (IF 27.4), Accounts of chemical research (IF 16.4), Angewandte Chemie International Edition (IF 16.1), ACS Nano (IF 15.8), Protein Cell (IF 13.6), Biomaterials (IF 12.8), Theranostics (IF 12.4), Nano Letters (IF 9.6), 等国际SCI 期刊发表论文近100篇（其中第一作者或通讯作者发表论文共48篇），编写专著《Tumor Ecosystem: An Ecological View of Cancer Growth and Survival》。专利授权项目6项（中国专利3项， 韩国专利 2 项，国际专利 1 项），受理项目2项（中国专利）。

联系方式：caipeie@mail.sysu.edu.cn

论文发表

  1. Junyue Fang#, Li Lin#, Xiaoyun Xiao, Jingwei Tian, Meng Zhang*, Phei Er Saw*. Advances of Immune Cells in the Pathogenesis and Targeted Therapy of Systemic Lupus Erythematosus. Journal of Cellular Immunology. 2024 Jun: e2401436.
  2. Wanrong Luo#, Jiabao Tan#, Xiaojiang Chen#, Chunxia Liu, Wenyue Zhang*, Phei Er Saw*, Baoming Luo*Bioactive Antiangiogenic Lipid Nanoparticles for Inhibiting Residual Tumor Growth after Insufficient Radiofrequency Ablation. ACS Applied Nano Materials,2024,Mar.
  3. Wenyue Zhang, Xiaodi Liu, Shuwen Cao, Qi Zhang, Xiaojiang Chen, Wanrong Luo, Jiabao Tan, Xiaolin Xu, Jing Tian, Phei Er Saw*, Baoming Luo*. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy. ACS Nano. 2023 Aug 8;17(15):14424-14441.
  4. Linzhuo Huang , Rui Xu, Weirong L, Li Lv, Chunhao Lin, Xianzhu Yang, Yandan Yao*, Phei Er Saw*, Xiaoding Xu*. Repolarization of macrophages to improve sorafenib sensitivity for combination cancer therapy. Acta Biomater. 2023 May;162:98-109.
  5. Shaomin Liu, Fengqian Zhang, Yixia Liang , Guo Wu, Rong Liu, Xiuling Li, Phei Er Saw* , Zhonghan Yang*.Nanoparticle (NP)-mediated APOC1 silencing to inhibit MAPK/ERK and NF-κB pathway and suppress breast cancer growth and metastasis. Exploration (Beijing). 2022 Jul 26;2(5):20220013.
  6. Phei Er Saw, Jianing Chen, Erwei Song. ChemoNETosis: A road to tumor therapeutic resistance. Cancer Cell 2023 Apr 10;41(4):655-657. 
  7. Shuwen Cao#, Wenyue Zhang#, Hehai Pan, Ziqi Huang, Mingyan Guo, Lei Zhang*, Xiaoding Xu*, Phei Er Saw*. Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy. Acta Biomater. 2023 Feb;157:500-510.
  8. Senlin Li, Siyu Chen, Zhihui Dong, Xingdong Song, Xiuling Li, Ziqi Huang, Huiru Li, Linzhuo Huang, Ganyuan Zhuang, Ran Lan, Mingyan Guo, Wende Li*, Phei Er Saw*, Lei Zhang*. Concurrent silencing of TBCE and drug delivery to overcome platinum-based resistance in liver cancer, Acta Pharmaceutica Sinica B, 2023 Mar; 13(3): 967-981.
  9. Xiaodi Liu#, Wenyue Zhang#, Yanni Xu#, Xiaolin Xu, Qiongchao Jiang, Jingliang Ruan, Ye Wu, Yingshi Zhou, Phei Er Saw*, Baoming Luo*. Targeting PI3Kγ/AKT Pathway Remodels LC3-Associated Phagocytosis Induced Immunosuppression After Radiofrequency Ablation,  Advanced Science, 2022 Jan 17;e2102182.
  10. Phei Er Saw, Jianing Chen, Erwei Song*. Targeting CAFs to overcome anticancer therapeutic resistance, Trends Cancer, 2022 Jul;8(7):527-555.

更多